Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics says global consumer goods company is looking at its technology

The company has been speaking to a range of commercial partners interested in evaluating its SkinBiotix technology ahead of its human studies, which are scheduled to commence later this year
Fresh faced model
SkinBioTherapeutics will share a sample of its material against which the third party will conduct its own in-house assessment

Skin health specialist SkinBioTherapeutics PLC (LON:SBTX) has granted access to its proprietary SkinBiotix technology to a major, global consumer goods company.

Having shared the initial pre-clinical data with a number of interested parties, one potential partner to date has progressed to a material transfer agreement - a standard agreement governing the transfer of material between parties enabling the recipient to assess the technology.

Should the unnamed consumer goods company like what it sees, the arrangement could lead to a commercial arrangement between the two companies.

While at this stage there can be no certainty that discussions will progress further than the initial sharing of the technology, SkinBioTherapeutics is encouraged by the level of interest that has been shown in its pre-clinical data.

WATCH: Industry heavyweights 'sitting up and taking notice' of SkinBio's technology

The company is initially targeting cosmetic skin care and in this market, SkinBioTherapeutics' skin microbiome technology is unusual in that its properties are supported by scientific data, SkinBio said.

The demonstrated properties support potential opportunities for the company in cosmetics, anti-infectives and dermatological indications (e.g. eczema).

"Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely through an MTA. Even at this early stage of its development, we are pleased to see that SkinBiotix is starting to generate a buzz in the skin care industry," said Dr Cath O’Neill, the chief executive officer of SkinBioTherapeutics. 

Motif’s joint broker, Northland Capital Partners, said: “It is encouraging that SkinBio Therapeutics is progressing to an MTA with a global consumer goods company. This demonstrates the potential commercial promise of the company’s technology.”

Shares in Motif were up 5.9% at 9p in lunchtime trading.

--- adds broker comment and share price reaction ---  

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

1528098797_Biotech-lab.jpg
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use